+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07851025

Randomized Study of Torvutatug Samrotecan with Bevacizumab Versus Bevacizumab Alone as First-line Maintenance for HRD-Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Led by AstraZeneca · Updated on 2026-10-01

950

Participants Needed

186

Research Sites

165 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of Torvutatug samrotecan and bevacizumab compared with bevacizumab alone as a first-line maintenance treatment in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are Homologous Recombination Deficient HRD negative. The study focuses on patients whose cancer has not progressed after completing first-line platinum-based chemotherapy and bevacizumab. Participants must have confirmed HRD-negative status and folate receptor alpha status. Participants will be randomly assigned to receive either Torvutatug samrotecan together with bevacizumab or bevacizumab alone. Both treatments are given intravenously. Eligible patients must have completed at least 6 cycles of platinum-based chemotherapy and at least 3 cycles of bevacizumab in combination with chemotherapy. The study is open-label and planned to last several years, with treatment continuing as maintenance therapy following initial chemotherapy. During the study, participants will have regular assessments including monitoring for cancer progression, survival, time to additional therapies, and quality of life. Researchers will also monitor the safety and side effects of the treatments. The main measurement is progression-free survival, tracked for up to approximately 5 years. Overall survival and other outcomes will be followed for up to approximately 7 years. Participants health and adverse events will be regularly evaluated throughout the study period.

CONDITIONS

Brief Title

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here